HDAC9 and neoplasm: In addition, a very interesting preclinical study by Kratzsch et al. [212] assessed the effect of 5-azacitidine (AZA; a ribonucleoside that is capable to incorporate into cellular RNA and DNA and acts as a HMA interfering with the DNMT activity [182,213]), valproic acid (HDAC inhibitor), temozolomide (a standard DNA alkylating chemotherapeutic positive control), and a bevacizumab (an angiogenesis inhibitor targeted therapy positive control) on the tumor growth and neovasculature status in the murine glioblastoma multiforme models.